CA2907079C - Combination of canagliflozin and probenecid for the treatment of hyperuricemia - Google Patents

Combination of canagliflozin and probenecid for the treatment of hyperuricemia Download PDF

Info

Publication number
CA2907079C
CA2907079C CA2907079A CA2907079A CA2907079C CA 2907079 C CA2907079 C CA 2907079C CA 2907079 A CA2907079 A CA 2907079A CA 2907079 A CA2907079 A CA 2907079A CA 2907079 C CA2907079 C CA 2907079C
Authority
CA
Canada
Prior art keywords
canagliflozin
probenecid
therapy
amount
hyperuricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2907079A
Other languages
English (en)
French (fr)
Other versions
CA2907079A1 (en
Inventor
Paul ROTHENBERG
Douglas K. Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2907079A1 publication Critical patent/CA2907079A1/en
Application granted granted Critical
Publication of CA2907079C publication Critical patent/CA2907079C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2907079A 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treatment of hyperuricemia Active CA2907079C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786738P 2013-03-15 2013-03-15
US61/786,738 2013-03-15
PCT/US2014/020958 WO2014149789A1 (en) 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treament of hyperuricemia

Publications (2)

Publication Number Publication Date
CA2907079A1 CA2907079A1 (en) 2014-09-25
CA2907079C true CA2907079C (en) 2021-06-22

Family

ID=50483479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907079A Active CA2907079C (en) 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treatment of hyperuricemia

Country Status (6)

Country Link
US (2) US20160022632A1 (enExample)
EP (1) EP2968235B1 (enExample)
JP (2) JP2016512817A (enExample)
CA (1) CA2907079C (enExample)
ES (1) ES2647526T3 (enExample)
WO (1) WO2014149789A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105548378B (zh) * 2015-12-03 2017-12-26 上海应用技术学院 一种卡格列净α、β异构体的分离方法
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
US11547685B2 (en) * 2017-12-11 2023-01-10 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
AU2019392750B2 (en) 2018-12-06 2025-07-10 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
US20200253878A1 (en) 2019-02-13 2020-08-13 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof
CN111057049B (zh) * 2019-11-18 2021-06-01 杭州华东医药集团新药研究院有限公司 一种卡格列净半水化合物的制备方法
EP4164624A4 (en) * 2020-06-10 2024-10-16 Arthrosi Therapeutics, Inc. METHODS OF TREATMENT OR PREVENTION OF CHRONIC KIDNEY DISEASE
CN112957318A (zh) * 2021-02-02 2021-06-15 河北科星药业有限公司 丙磺舒溶液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
BRPI0913129A2 (pt) * 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用

Also Published As

Publication number Publication date
JP2019089825A (ja) 2019-06-13
JP2016512817A (ja) 2016-05-09
EP2968235A1 (en) 2016-01-20
US20160022632A1 (en) 2016-01-28
WO2014149789A1 (en) 2014-09-25
EP2968235B1 (en) 2017-09-13
US20170368025A1 (en) 2017-12-28
CA2907079A1 (en) 2014-09-25
ES2647526T3 (es) 2017-12-22

Similar Documents

Publication Publication Date Title
CA2907079C (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
EP2291189B1 (en) Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
CN102834099B (zh) Dgat1抑制剂的用途
US7834056B2 (en) Pharmaceutical composition for gout
CA2737163C (en) Methods of treatment of hyperuricemia and associated disease states
HK1248124A1 (zh) 用於治疗肥胖症和肥胖症相关疾病的包含卡格列净和芬特明的协同治疗
Wehring et al. Diabetes mellitus associated with clozapine therapy
WO2002078692A1 (en) Method of treatment
US20070287685A1 (en) Medicinal composition containing FBPase inhibitor
US20070259928A1 (en) Medicinal Composition for Treating Diabetes
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
WO2024141073A1 (en) Pharmaceutical combinations and compositions, and methods of use thereof
CN1057207C (zh) 治疗人类骨质疏松症的协同药物结合物
Hassan Drugs Used in GOUT
JPH01216931A (ja) 血中尿酸濃度低減用治療剤
WO1999007412A1 (en) Remedies for diseases associated with bone resorption
HK1104477A (en) Medicinal composition containing fbpase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304